Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738468 | 0.83 | ALDH1A1 (0.42) | KMT2AALDH1A1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL29659123 | 0.83 | MAPT (0.46) | KMT2AALDH1A1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL631579 | 0.83 | MAPT (0.46) | KMT2AALDH1A1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL26325050 | 0.82 | ALDH1A1 (0.50) | KMT2AALDH1A1MEN1MAPTHTR2C | |
| SCHEMBL15757174 | 0.82 | MAPT (0.49) | KMT2AALDH1A1MEN1MAPTHTR2C | |
| SCHEMBL30536438 | 0.80 | ALDH1A1 (0.55) | KMT2AALDH1A1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL1803111 | 0.80 | ALDH1A1 (0.55) | KMT2AALDH1A1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL21872428 | 0.79 | KMT2A (0.47) | KMT2AALDH1A1MEN1MAPTHTR2C | |
| SCHEMBL17048383 | 0.78 | MAPT (0.40) | KMT2AALDH1A1MEN1MAPTTSHR | |
| SCHEMBL8292658 | 0.78 | ABL1 (0.40) | KMT2AALDH1A1MEN1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2021219828-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2021-11-04 | — | — | WO | disclosed |
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7951950-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| CN-101146776-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2008-03-19 | — | — | CN | disclosed |
| EP-1861372-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| US-20060241109-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006091674-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20040082661-A1 | Urea derivatives having vanilloid receptor (vr1) antagonist activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1366020-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072536-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | KMT2A 1095/4885ALDH1A1 1859/4885MEN1 1392/4885 |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 | KMT2A 869/4885ALDH1A1 3108/4885MEN1 2273/4885 |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 | KMT2A 835/4885ALDH1A1 2167/4885MEN1 2129/4885 |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | KMT2A 3738/4885ALDH1A1 1173/4885MEN1 3778/4885 |
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KMT2A 461/4885ALDH1A1 707/4885MEN1 2981/4885 |
| US-20040082661-A1 | Urea derivatives having vanilloid receptor (vr1) antagonist activity | UTS2R, TRPV1, VRK1 | KMT2A 4125/4885ALDH1A1 1337/4885MEN1 4379/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | KMT2A 461/4885ALDH1A1 707/4885MEN1 2981/4885 |
| US-20060241109-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGER2, PTGDR2, PTGER1 | KMT2A 4505/4885ALDH1A1 2836/4885MEN1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.